Amylin: Finally ready for prime time?

After seven years, six Phase III trials and one lost partner, Amylin Pharmaceuticals Inc. believes that it finally has the clinical data necessary to submit applications in mid-2000 for U.S. and European marketing approval of its Symlin pramlintide analog of the hormone amylin to treat Type I diabetes and insulin-dependent Type II diabetes.

Now, however, the company must organize the complex data set both to establish the preponderance of the data in a single application and to support a final product label...